Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00549510 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00549510 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 29 participants.
The verdict
NCT00549510, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This will be an open-label, single-dose, non-randomized, five-period crossover study in healthy volunteers. The duration of the study will last up to eleven weeks from screening to follow-up. PK samples will be taken.
Interventions
- DRUG COREG CR and lisinopril (FDC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00549510
The ClinicalTrials.gov registry entry for NCT00549510 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COREG CR and lisinopril (FDC) is the first listed.
NCT00549510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00549510 about?
NCT00549510 is a clinical study titled "Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.". This will be an open-label, single-dose, non-randomized, five-period crossover study in healthy volunteers. The duration of the study will last up to eleven weeks from screening to follow-up. PK samples will be taken.
What is the current status of trial NCT00549510?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2007-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00549510?
The interventions under investigation include: COREG CR and lisinopril (FDC) (DRUG).
Who is sponsoring clinical trial NCT00549510?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.